Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication: results of a large-scale, multicenter cohort study in Japan

Gastric Cancer

Volumn 19, Issue 3, 2016, Pages 911-918

  Mori, Genki ^a   Nakajima, Takeshi ^a   Asada, Kiyoshi ^b   Shimazu, Taichi ^c   Yamamichi, Nobutake ^d   Maekita, Takao ^e   Yokoi, Chizu ^f   Fujishiro, Mitsuhiro ^d   Gotoda, Takuji ^g   Ichinose, Masao ^e   Ushijima, Toshikazu ^b   Oda, Ichiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Helicobacter pylori; Incidence; Multivariate analysis; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; ATROPHY; BACTERIAL CLEARANCE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; DISEASE SURVEILLANCE; EARLY CANCER; ENDOSCOPIC SURGERY; FEMALE; FOLLOW UP; GASTRIC MUCOSA; GENDER; HELICOBACTER PYLORI; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METACHRONOUS GASTRIC CANCER; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH CANCER; ADVERSE EFFECTS; CANCER STAGING; CLINICAL TRIAL; COMPLICATION; ENDOSCOPY; GASTRECTOMY; GASTROSCOPY; HELICOBACTER INFECTION; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; STOMACH NEOPLASMS; SURVIVAL RATE; VIROLOGY;

ADULT; AGED; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84944609178     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-015-0544-6     Document Type: Article

References (41)

1. Isomoto H, Shikuwa S, Yamaguchi N, Fukuda E, Ikeda K, Nishiyama H, et al. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut. 2009;58:331–6.
2. Goto O, Fujishiro M, Kodashima S, Ono S, Omata M. Outcomes of endoscopic submucosal dissection for early gastric cancer with special reference to validation for curability criteria. Endoscopy. 2009;41:118–22.
3. Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg. 2010;97:868–71.
4. Abe S, Oda I, Suzuki H, Nonaka S, Yoshinaga S, Odagaki T, et al. Short- and long-term outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Endoscopy. 2013;45:703–7.
5. Oda I, Oyama T, Abe S, Ohnita K, Kosaka T, Hirasawa K, et al. Preliminary results of multicenter questionnaire study on long-term outcomes of curative endoscopic submucosal dissection for early gastric cancer. Dig Endosc. 2014;26:214–9.
6. Ohnita K, Isomoto H, Shikuwa S, Yajima H, Minami H, Matsushima K, et al. Early and long-term outcomes of endoscopic submucosal dissection for early gastric cancer in a large patient series. Exp Ther Med. 2014;7:594–8.
7. Suzuki H, Oda I, Abe S, Sekiguchi M, Mori G, Nonaka S, et al. High rate of 5-year survival among patients with early gastric cancer undergoing curative endoscopic submucosal dissection. Gastric Cancer. 2015. doi:10.1007/s10120-015-0469-0.
8. Nakajima T, Oda I, Gotoda T, Hamanaka H, Eguchi T, Yokoi C, et al. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? Gastric Cancer. 2006;9:93–8.
9. Kato M, Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD Study Group. Gut. 2013;62:1425–32.
10. Shiotani A, Haruma K, Graham DY. Metachronous gastric cancer after successful Helicobacter pylori eradication. World J Gastroenterol. 2014;20:11552–9.
11. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7.
12. Shiotani A, Uedo N, Iishi H, Yoshiyuki Y, Ishii M, Manabe N, et al. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. Digestion. 2008;78:113–9.
13. Maehata Y, Nakamura S, Fujisawa K, Esaki M, Moriyama T, Asano K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012;75:39–46.
14. Choi J, Kim SG, Yoon H, Im JP, Kim JS, Kim WH, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2014;12:793–800.e1.
15. Bae SE, Jung HY, Kang J, Park YS, Baek S, Jung JH, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol. 2014;109:60–7.
16. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 2006;12:989–95.
17. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol. 2007;40:142–50.
18. Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer. 2009;124:905–10.
19. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 2010;70:1430–40.
20. Nakajima T, Enomoto S, Yamashita S, Ando T, Nakanishi Y, Nakazawa K, et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol. 2010;45:37–44.
21. Nanjo S, Asada K, Yamashita S, Nakajima T, Nakazawa K, Maekita T, et al. Identification of gastric cancer risk markers that are informative in individuals with past H. pylori infection. Gastric Cancer. 2012;15:382–8.
22. Ushijima T, Hattori N. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin Cancer Res. 2012;18:923–9.
23. Asada K, Nakajima T, Shimazu T, Yamamichi N, Maekita T, Yokoi C, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut. 2015;64:388–96.
24. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.
25. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.
26. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst. 2000;92:1881–8.
27. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.
28. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974–83.
29. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42(Suppl 17):21–7.
30. Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther. 2007;25:805–12.
31. Ogura K, Hirata Y, Yanai A, Shibata W, Ohmae T, Mitsuno Y, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol. 2008;42:279–83.
32. Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer. 2009;125:2697–703.
33. Mabe K, Takahashi M, Oizumi H, Tsukuma H, Shibata A, Fukase K, et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol. 2009;15:4290–7.
34. Chen HN, Wang Z, Li X, Zhou ZG. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer. 2015. doi:10.1007/s10120-015-0462-7.
35. Take S, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011;46:318–24.
36. Mitsunaga A, Tagata T, Hamano T, Teramoto H, Kan M, Mitsunaga Y, et al. Metachronous early gastric cancer over a period of 13 years after eradication of Helicobacter pylori. Clin J Gastroenterol. 2014;7:490–5.
37. Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40:250–60.
38. Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S, et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev. 2006;15:2317–21.
39. Kato M, Asaka M. Recent development of gastric cancer prevention. Jpn J Clin Oncol. 2012;42:987–94.
40. Massarrat S, Stolte M. Development of gastric cancer and its prevention. Arch Iran Med. 2014;17:514–20.
41. Park SY, Lim SO, Ki HS, Jun CH, Park CH, Kim HS, et al. Low pepsinogen I level predicts multiple gastric epithelial neoplasias for endoscopic resection. Gut Liver. 2014;8:277–81.